Seagen Inc. (SGEN): Price and Financial Metrics

Seagen Inc. (SGEN): $212.15

0.09 (-0.04%)

POWR Rating

Component Grades








Add SGEN to Watchlist
Sign Up

Industry: Biotech




#94 of 393

in industry

SGEN Price/Volume Stats

Current price $212.15 52-week high $217.08
Prev. close $212.24 52-week low $116.08
Day low $212.12 Volume 1,286,700
Day high $213.50 Avg. volume 1,369,907
50-day MA $201.01 Dividend yield N/A
200-day MA $182.64 Market Cap 39.82B

SGEN Stock Price Chart Interactive Chart >

SGEN Stock Summary

  • SGEN has a market capitalization of $40,111,048,710 -- more than approximately 94.36% of US stocks.
  • With a one year PEG ratio of 1,432.17, SEAGEN INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.76% of US stocks.
  • SGEN's price/sales ratio is 18.55; that's higher than the P/S ratio of 94.35% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SEAGEN INC are QRVO, CDNS, NXPI, EA, and WDC.
  • SGEN's SEC filings can be seen here. And to visit SEAGEN INC's official web site, go to

SGEN Valuation Summary

  • SGEN's price/sales ratio is 18.6; this is 365% higher than that of the median Healthcare stock.
  • SGEN's price/earnings ratio has moved down 47 over the prior 243 months.

Below are key valuation metrics over time for SGEN.

Stock Date P/S P/B P/E EV/EBIT
SGEN 2023-09-22 18.6 15.3 -55.3 -56.1
SGEN 2023-09-21 17.9 14.8 -53.4 -54.2
SGEN 2023-09-20 18.0 14.8 -53.6 -54.3
SGEN 2023-09-19 18.1 14.9 -53.9 -54.7
SGEN 2023-09-18 18.0 14.8 -53.6 -54.4
SGEN 2023-09-15 18.1 14.9 -53.9 -54.7

SGEN Growth Metrics

    Its year over year cash and equivalents growth rate is now at -30.16%.
  • The 4 year net cashflow from operations growth rate now stands at -23.05%.
  • The 3 year cash and equivalents growth rate now stands at 209.71%.
SGEN's revenue has moved up $216,598,000 over the prior 15 months.

The table below shows SGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,962.412 -453.751 -610.308
2022-09-30 1,864.113 -657.694 -636.765
2022-06-30 1,777.873 -589.819 -739.796
2022-03-31 1,668.849 -590.493 -689.545
2021-12-31 1,574.371 -499.007 -674.471
2021-09-30 1,745.814 -26.48 -332.748

SGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SGEN has a Quality Grade of C, ranking ahead of 74.02% of graded US stocks.
  • SGEN's asset turnover comes in at 0.44 -- ranking 102nd of 681 Pharmaceutical Products stocks.
  • BPMC, OCGN, and OTLC are the stocks whose asset turnover ratios are most correlated with SGEN.

The table below shows SGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.440 0.836 -0.133
2021-06-30 0.640 0.882 0.271
2021-03-31 0.693 0.889 0.354
2020-12-31 0.773 0.900 0.398
2020-09-30 0.788 0.910 0.374
2020-06-30 0.475 0.901 -0.184

SGEN Price Target

For more insight on analysts targets of SGEN, see our SGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $188.25 Average Broker Recommendation 1.58 (Moderate Buy)

Seagen Inc. (SGEN) Company Bio

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. (Source:Wikipedia)

SGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream

Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher

These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.

Omor Ibne Ehsan on InvestorPlace | September 27, 2023

Signal Says Buy Calls on This Biotech Stock

SGEN's peak comes amid historically low implied volatility

Yahoo | September 25, 2023

The Hedge Fund That Made a Killing Betting Against Lina Khan

The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals. In both cases, the FTC’s intervention spooked investors and sent shares of the target companies swinging.

Yahoo | September 24, 2023

Stocks to Watch Friday: Alibaba, Activision, Microsoft, Ford, Meta Platforms

**↗️** [**Microsoft (MSFT)**](, [**Activision Blizzard (ATVI)**]( A modified deal by the software giant to buy the videogame publisher was [cleared by the U.

Yahoo | September 22, 2023

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has spread to surrounding organs or muscles, or othe

Yahoo | September 22, 2023

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo 2.04%
3-mo N/A
6-mo 3.49%
1-year 55.05%
3-year 9.88%
5-year 156.34%
YTD 65.08%
2022 -16.88%
2021 -11.73%
2020 53.28%
2019 101.66%
2018 5.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!